Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +25

Bleakley Financial Group LLC Acquires 24,649 Shares of Gilead Sciences ...

AI-generated analysis

πŸ“ˆ Bleakley Financial Group LLC raised its Gilead holdings by 80.3% to 55,332 shares worth $7.71 million during the first quarter.

🏦 Principal Financial Group Inc. increased its stake by 0.4%, now owning 1,769,886 shares valued at $246.67 million.

πŸ’° Gilead Sciences paid a quarterly dividend of $0.82 per share on June 29th with an annualized yield of 2.5%.

πŸ“Š The stock has a market cap of $161.45 billion and trades at a P/E ratio of 17.72.

πŸ“‰ Insider Johanna Mercier sold 28,000 shares for $3.68 million under a pre-arranged trading plan.

πŸ“‰ CFO Andrew D. Dickinson sold 3,000 shares for $376,200 following the quarterly dividend payment.

πŸ“‰ Total insider sales over the last ninety days reached 77,000 shares valued at $9.98 million.

🎯 Wall Street Zen upgraded Gilead from a 'hold' to a 'buy' rating in a recent research report.

πŸ“‰ Cantor Fitzgerald maintained an 'overweight' rating with a price objective of $155.00.

πŸ“‰ Morgan Stanley lowered its target price to $166.00 but retained an 'overweight' rating.

πŸ“‰ Leerink Partners reduced its target price from $148.00 to $146.00 in a report dated May 8th.

πŸ“‰ Truist Financial cut its price target to $156.00 while maintaining a 'buy' rating.

πŸ₯ Gilead focuses on antiviral therapies for HIV and hepatitis, plus oncology and cell therapy.

πŸ“ˆ Institutional investors own 83.67% of the company's outstanding stock.

Bullish Signals
  • Bleakley Financial Group LLC significantly increased its position by 80.3%, signaling strong institutional confidence in the biopharmaceutical sector.
  • Principal Financial Group Inc. boosted its stake, adding 7,880 shares to a massive existing portfolio valued at over $246 million.
  • Chicago Partners Investment Group LLC raised its holdings by 8.3%, acquiring an additional 590 shares worth over $1 million.
  • New institutional entrants Bedel Financial Consulting Inc., IFC Advisors LLC, and HBW Advisory Services LLC initiated or increased positions in Gilead.
  • Wall Street Zen upgraded the stock from a 'hold' to a 'buy' rating, indicating improved analyst sentiment.
  • Cantor Fitzgerald reiterated an 'overweight' rating with a specific price objective of $155.00.
  • Morgan Stanley maintains an 'overweight' rating despite lowering its target price, suggesting continued long-term confidence.
  • Truist Financial assigned a 'buy' rating to the stock even after reducing its price target slightly.
  • The company offers a consistent dividend yield of 2.5% with a manageable payout ratio of 44.69%.
  • Institutional ownership remains robust at 83.67%, indicating broad market acceptance and stability.
Risk Factors
  • CEO Johanna Mercier sold 28,000 shares worth $3.68 million, representing an 18.21% decrease in her personal ownership.
  • CFO Andrew D. Dickinson sold 3,000 shares worth $376,200, reducing his stake by 1.72%.
  • Total insider selling over the last ninety days reached $9.98 million, which may indicate profit-taking or portfolio rebalancing.
  • Leerink Partners lowered its price target from $148.00 to $146.00, reflecting a slight bearish adjustment.
  • Morgan Stanley reduced its price target from $168.00 to $166.00, indicating some analysts see limited upside near current levels.
  • Truist Financial cut its price target from $157.00 to $156.00, suggesting a cautious outlook on immediate valuation.
Full Analysis
Bleakley Financial Group LLC significantly increased its stake in Gilead Sciences, Inc. (GILD) by 80.3% during the first quarter, purchasing an additional 24,649 shares to hold a total of 55,332 shares valued at $7.71 million. Other institutional investors also adjusted their positions, with Principal Financial Group Inc. boosting its stake by 0.4% and Chicago Partners Investment Group LLC increasing holdings by 8.3%. New entrants including Bedel Financial Consulting Inc., IFC Advisors LLC, and HBW Advisory Services LLC added to their Gilead positions, while institutional ownership remains high at 83.67%. Gilead Sciences reported a quarterly dividend of $0.82 per share paid on June 29th, representing an annualized yield of 2.5% with a payout ratio of 44.69%. The stock currently trades with a market capitalization of $161.45 billion and a price-to-earnings ratio of 17.72. Analyst sentiment is mixed but generally positive, with a consensus target price of $159.04 from twenty-six equities research analysts, though recent reports show some firms lowering their price targets while others maintain buy ratings. Insider trading activity shows net selling over the last ninety days, totaling 77,000 shares valued at approximately $9.98 million. CEO Johanna Mercier sold 28,000 shares under a pre-arranged Rule 10b5-1 plan, and CFO Andrew D. Dickinson sold 3,000 shares. Despite these sales, insiders still hold significant equity, with the CEO owning roughly $16.5 million and the CFO holding approximately $21.5 million in company stock.